FDA Talks Tough To Tyco, Cites Baxter For QS Lapses In Warning Letters
This article was originally published in The Gray Sheet
Executive Summary
Baxter has implemented 100% leak testing as part of its efforts to respond to a recent FDA warning letter that detailed quality systems infractions
You may also be interested in...
Tyco/Radionics Seeks Quality System Auditor Following FDA Warning Letter
Tyco Healthcare Group subsidiary Radionics should stop shipping certain products that FDA believes pose sterility concerns, the agency suggests in a warning letter dated March 8 and released March 26
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.